Corton Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Corton Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,940	Closed	-$57.2K	–	202
2025 Q2	$57.2K	Buy	+14,940	New	+$38.6K	0.07%	328

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Corton Capital's ALDX Position: Q3 2025 in Review

Corton Capital sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 14,940 shares — an estimated $57.2K sold.

Corton Capital first reported a position in ALDX in Q2 2025 and held it in 1 quarter. The position peaked at $57.2K in Q2 2025. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

Corton Capital reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 14,940 Aldeyra Therapeutics shares in Q3 2025, an estimated $57.2K.
Corton Capital first reported a position in Aldeyra Therapeutics in Q2 2025 and held it in 1 quarter.
Corton Capital's Aldeyra Therapeutics position peaked at $57.2K in Q2 2025.
130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.